benazepril Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 299 86541-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • benazepril
  • cibacen
  • benazepril hydrochloride
  • benazepril HCl
prodrug of benazeprilat inhibit angiotensin-converting enzyme (ACE) and results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion
  • Molecular weight: 424.50
  • Formula: C24H28N2O5
  • CLOGP: 1.82
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -4.61
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
7.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 78 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.13 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 18 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
June 25, 1991 FDA US PHARMS HOLDINGS I

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 514.07 37.66 108 642 8288 2349047
Completed suicide 305.32 37.66 85 665 20949 2336386
Drug hypersensitivity 186.17 37.66 71 679 46572 2310763
Swollen tongue 166.91 37.66 40 710 5303 2352032
Dizziness 133.80 37.66 60 690 58605 2298730
Toxicity to various agents 119.79 37.66 47 703 32707 2324628
Hypotension 106.18 37.66 43 707 32393 2324942
Cough 101.88 37.66 42 708 33075 2324260
Blood pressure inadequately controlled 98.64 37.66 19 731 881 2356454
Swelling face 86.54 37.66 27 723 9466 2347869
Vasodilatation 72.75 37.66 13 737 396 2356939
Oedema peripheral 65.68 37.66 28 722 23735 2333600
Acute kidney injury 64.33 37.66 29 721 28093 2329242
Blood pressure increased 63.98 37.66 25 725 16961 2340374
Hyperkalaemia 58.85 37.66 18 732 5875 2351460
Kounis syndrome 57.77 37.66 10 740 252 2357083
Asthenia 55.71 37.66 31 719 46895 2310440
Fatigue 54.81 37.66 38 712 84835 2272500
Dyspnoea 52.57 37.66 36 714 78697 2278638
Nausea 51.74 37.66 41 709 112148 2245187
Oropharyngeal swelling 51.64 37.66 9 741 236 2357099
Headache 47.29 37.66 34 716 80145 2277190
Dysphagia 45.18 37.66 18 732 12787 2344548
Blood creatinine increased 44.94 37.66 17 733 10516 2346819
Palpitations 44.09 37.66 19 731 16437 2340898
Hypertension 43.49 37.66 22 728 27339 2329996
Product complaint 41.64 37.66 13 737 4525 2352810
Product substitution issue 40.22 37.66 13 737 5056 2352279
Cardiac failure 39.20 37.66 16 734 12078 2345257
Intestinal ischaemia 38.23 37.66 9 741 1082 2356253

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 558.44 35.08 128 582 9536 1736535
Completed suicide 215.62 35.08 68 642 16244 1729827
Swollen tongue 137.68 35.08 33 677 2775 1743296
Acute kidney injury 105.89 35.08 50 660 34894 1711177
Cough 98.91 35.08 40 670 19157 1726914
Shock 96.62 35.08 27 683 4134 1741937
Drug hypersensitivity 82.90 35.08 33 677 15102 1730969
Hypotension 76.18 35.08 38 672 29616 1716455
Lip swelling 68.76 35.08 19 691 2776 1743295
Dizziness 68.08 35.08 37 673 34324 1711747
Blood pressure inadequately controlled 61.69 35.08 13 697 600 1745471
Blood creatinine increased 61.25 35.08 26 684 13920 1732151
Swelling face 55.77 35.08 18 692 4465 1741606
Concomitant disease progression 51.91 35.08 11 699 521 1745550
Cardiac arrest 51.60 35.08 24 686 15906 1730165
Drug ineffective 49.30 35.08 38 672 63763 1682308
Overdose 47.46 35.08 23 687 16678 1729393
Dyspnoea 44.55 35.08 33 677 52026 1694045
Hyperkalaemia 44.43 35.08 18 692 8529 1737542
Hypertension 44.14 35.08 23 687 19425 1726646
Blood pressure increased 43.69 35.08 19 691 10734 1735337
Suicide attempt 43.42 35.08 17 693 7364 1738707
Toxicity to various agents 43.10 35.08 26 684 29115 1716956
Intentional overdose 42.79 35.08 17 693 7653 1738418
Lymphomatoid papulosis 35.65 35.08 6 704 79 1745992
Stent placement 35.12 35.08 9 701 979 1745092

Pharmacologic Action:

SourceCodeDescription
ATC C09AA07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
FDA PE N0000178477 Decreased Blood Pressure
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:50266 prodrug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Acute scleroderma renal crisis off-label use 236503001
Diastolic heart failure off-label use 418304008 DOID:9775
Hypertension due to Scleroderma off-label use
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Jaundice contraindication 18165001
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Azotemia contraindication 445009001
Intestinal Angioedema contraindication
Head and Neck Angioedema contraindication
Hemodialysis with High-Flux Membrane contraindication
Severe Aortic Valve Stenosis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.9 acidic
pKa2 5.34 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.70 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.77 CHEMBL

External reference:

IDSource
4020817 VUID
N0000148336 NUI
C0053091 UMLSCUI
D00620 KEGG_DRUG
108572003 SNOMEDCT_US
4020817 VANDF
003597 NDDF
d00730 MMSL
18867 RXNORM
372511001 SNOMEDCT_US
CHEMBL838 ChEMBL_ID
DB00542 DRUGBANK_ID
CHEMBL1694 ChEMBL_ID
CHEMBL1192519 ChEMBL_ID
JRM708L703 UNII
6128 INN_ID
86541-78-8 SECONDARY_CAS_RN
CHEBI:3011 CHEBI
6374 IUPHAR_LIGAND_ID
C052133 MESH_SUPPLEMENTAL_RECORD_UI
C044946 MESH_SUPPLEMENTAL_RECORD_UI
5362124 PUBCHEM_CID
DB14125 DRUGBANK_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0364 CAPSULE 20 mg ORAL NDA 18 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0379 CAPSULE 40 mg ORAL NDA 18 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0405 CAPSULE 10 mg ORAL NDA 18 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0406 CAPSULE 20 mg ORAL NDA 18 sections
Amlodipine and Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7370 CAPSULE 10 mg ORAL ANDA 18 sections
Amlodipine and Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7371 CAPSULE 10 mg ORAL ANDA 18 sections
Amlodipine and Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7372 CAPSULE 20 mg ORAL ANDA 18 sections
Amlodipine and Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7373 CAPSULE 20 mg ORAL ANDA 18 sections
Amlodipine and Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7670 CAPSULE 40 mg ORAL ANDA 18 sections
Amlodipine and Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7671 CAPSULE 40 mg ORAL ANDA 18 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0048 TABLET, FILM COATED 40 mg ORAL ANDA 17 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0053 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 13 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0505 TABLET, FILM COATED 5 mg ORAL ANDA 17 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0820 TABLET, FILM COATED 20 mg ORAL ANDA 17 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0441 TABLET, FILM COATED 5 mg ORAL ANDA 17 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0443 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0444 TABLET, FILM COATED 20 mg ORAL ANDA 17 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0447 TABLET, FILM COATED 40 mg ORAL ANDA 17 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-4725 TABLET, FILM COATED 5 mg ORAL ANDA 13 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-4735 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-4745 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-4775 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0227 TABLET 10 mg ORAL NDA authorized generic 14 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0228 TABLET 20 mg ORAL NDA authorized generic 14 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0229 TABLET 20 mg ORAL NDA authorized generic 14 sections
amlodipine besylate and benazepril hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0615-1397 CAPSULE 10 mg ORAL NDA 18 sections